BioCentury | May 28, 2020
Distillery Therapeutics

microRNA cluster identified as targets for ischemic stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Targeting the miR-15a/miR-16-1 cluster to enhance blood-brain barrier function could treat ischemic stroke. In mice with middle cerebral artery occlusion-induced stroke, endothelial cell-specific knockout of the miR-15a/miR-16-1 cluster reduced infarct...
BioCentury | Feb 1, 2020
Company News

BioNTech’s approach to matching technologies to tumors

Though often compared to Moderna, BioNTech is not an mRNA company -- it’s a cancer company. The German biotech has amassed six different technologies in its 12-year history to address the entire continuum of solid...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Jan 4, 2020
Tools & Techniques

BioNTech tackles solid tumors by pairing CAR Ts with RNA vaccines

BioNTech is marrying two of its core technologies -- RNA therapeutics and engineered cell therapies -- to solve some of the biggest challenges of bringing CAR T cells to solid tumors. It believes that together,...
BioCentury | Nov 22, 2019
Product Development

The quiet disrupters: DNA-encoded and RNA-encoded antibodies

A new approach to streamlining biologics manufacturing could soon catch on--encoding the therapies in DNA or RNA, which enjoins the patient to produce the proteins in vivo . While the biggest upside may be the speed...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
BioCentury | Sep 14, 2018
Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
BioCentury | Sep 10, 2018
Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
BioCentury | Aug 16, 2018
Distillery Techniques

Assays and screens; drug properties

TECHNOLOGY: Cellular assays; toxicology Human kidney cells cultured on decellularized rat kidney extracellular matrix (ECM) scaffolds could be used to screen compounds for nephrotoxicity. The method involved treating rat kidney tissue samples with detergent and...
Items per page:
1 - 10 of 102